Canada Pension Plan Investment Board Purchases 2,186 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Canada Pension Plan Investment Board increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 298,241 shares of the medical equipment provider’s stock after acquiring an additional 2,186 shares during the quarter. Canada Pension Plan Investment Board owned about 0.15% of Zimmer Biomet worth $32,368,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its position in shares of Zimmer Biomet by 12.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider’s stock worth $1,404,638,000 after purchasing an additional 1,215,935 shares in the last quarter. American Century Companies Inc. increased its position in Zimmer Biomet by 12.6% during the 2nd quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock valued at $701,521,000 after buying an additional 722,041 shares in the last quarter. Boston Partners raised its stake in Zimmer Biomet by 26.3% in the first quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider’s stock valued at $437,413,000 after buying an additional 691,191 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Zimmer Biomet by 11.3% in the first quarter. Van ECK Associates Corp now owns 3,158,560 shares of the medical equipment provider’s stock worth $416,866,000 after acquiring an additional 320,002 shares in the last quarter. Finally, AMF Tjanstepension AB purchased a new stake in shares of Zimmer Biomet during the first quarter worth about $30,300,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 0.1 %

Shares of Zimmer Biomet stock opened at $106.42 on Monday. The firm has a 50-day simple moving average of $109.83 and a two-hundred day simple moving average of $115.38. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $133.90. The company has a market cap of $21.89 billion, a P/E ratio of 23.03, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. The company had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.94 billion. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. Zimmer Biomet’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.82 EPS. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.02 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.90%. The ex-dividend date is Monday, September 30th. Zimmer Biomet’s payout ratio is presently 20.78%.

Analyst Ratings Changes

Several equities analysts recently commented on ZBH shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, September 17th. JPMorgan Chase & Co. lowered their price objective on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research note on Monday, September 16th. Evercore ISI reissued an “in-line” rating and issued a $113.00 target price on shares of Zimmer Biomet in a research report on Thursday, September 5th. Royal Bank of Canada lowered their price target on Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Finally, UBS Group cut their price objective on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a report on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average price target of $125.17.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.